Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF)
作者: Ruth NabisereJoseph MusaaziPaolo DentiFlorence AberMohammed LamordeKelly E. DooleyRob AarnoutseDerek J. SloanChristine Sekaggya-Wiltshire
作者单位: 1Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda
2Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
3Division of Clinical Pharmacology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
4Radbound University, Radbound, Netherlands
5Division of Infection and Global Health, School of Medicine, University of St. Andrews, St. Andrews, Scotland
刊名: Trials, 2020, Vol.21 (1), pp.2994-2996
来源数据库: Springer Nature Journal
DOI: 10.1186/s13063-020-4132-7
关键词: RifamycinsAntiretroviralsHIVPharmacokineticsTuberculosis
英文摘要: Abstract(#br)Background(#br)Tuberculosis (TB) is a significant public health problem that causes substantial morbidity and mortality. Current first-line anti-TB chemotherapy, although very effective, has limitations including long-treatment duration with a possibility of non-adherence, drug interactions, and toxicities. Dose escalation of rifampicin, an important drug within the regimen, has been proposed as a potential route to higher treatment efficacy with shorter duration and some studies have suggested that dose escalation is safe; however, these have almost entirely been conducted among human immunodeficiency (HIV)-negative TB patients. TB-HIV co-infected patients on antiretroviral therapy (ART) are at increased risk of drug-drug interactions and drug-related toxicities. This study...
全文获取路径: Springer Nature  (合作)
影响因子:2.206 (2012)